AGENDA ITEM
Wednesday, February 24, 2021

9:30 Welcome & Introductions

10:00 Rabies Vaccines
Introduction
Summary of Pre-exposure prophylaxis (PrEP) considerations including cost of PrEP, GRADE, and ETR
Background about rabies post-exposure prophylaxis
Workgroup interpretations about rabies immune globulin
Summary and next steps

12:00 Break
12:30 Public Comment
1:00 Votes

1:20 Dengue Vaccine
Introduction
Results of dengue test independent evaluation
Draft recommendations using the Evidence to Recommendations Framework

2:20 Tick-borne Encephalitis (TBE) Vaccine
Introduction
TBE epidemiology in TBE endemic areas
TBE among US civilian travelers and laboratory workers
TBE among military personnel and dependents
Summary of risks of TBE for U.S. travelers and laboratory workers and next steps

3:30 Break
3:40 Ebola Vaccine
Introduction
Background on state designated Ebola Treatment Centers (ETC) and Laboratory Response Network (LRN) facilities and survey results
Review of preliminary workgroup discussions

4:45 Hepatitis Vaccine
Introduction
Background
Economic analysis

5:30 Adjourn

Thursday, February 25, 2021

9:30 Welcome & Introductions

9:40 Agency Updates

10:00 Pneumococcal Vaccines
Introduction
Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US adults
PCV20 Phase 2/3 study results in adults
PCV15 Phase 2/3 study results in adults, including adults with underlying conditions
Considerations for PCV15 and PCV 20 use in adults

12:00 Break
12:20 Zoster Vaccines
Introduction
Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV)
RZV risk-benefit analysis
Work group interpretation

AGENDA ITEM
November 24, 2021

9:30 Welcome & Introductions

10:00 Rabies Vaccines
Introduction
Summary of Pre-exposure prophylaxis (PrEP) considerations including cost of PrEP, GRADE, and ETR
Background about rabies post-exposure prophylaxis
Workgroup interpretations about rabies immune globulin
Summary and next steps

12:00 Break
12:30 Public Comment
1:00 Votes

1:20 Dengue Vaccine
Introduction
Results of dengue test independent evaluation
Draft recommendations using the Evidence to Recommendations Framework

2:20 Tick-borne Encephalitis (TBE) Vaccine
Introduction
TBE epidemiology in TBE endemic areas
TBE among US civilian travelers and laboratory workers
TBE among military personnel and dependents
Summary of risks of TBE for U.S. travelers and laboratory workers and next steps

3:30 Break
3:40 Ebola Vaccine
Introduction
Background on state designated Ebola Treatment Centers (ETC) and Laboratory Response Network (LRN) facilities and survey results
Review of preliminary workgroup discussions

4:45 Hepatitis Vaccine
Introduction
Background
Economic analysis

5:30 Adjourn
Introduction of the Evidence to Recommendations Framework for use of RZV in immunocompromised adults

Dr. Tara Anderson (CDC/NCIRD)

1:30 **Influenza Vaccines**

Introduction

Dr. Keipp Talbot (ACIP, WG Chair)

Influenza surveillance update

Dr. Lisa Grohskopf (CDC/NCIRD)

Work group considerations

Dr. Lisa Grohskopf (CDC/NCIRD)

2:15 **Break**

2:25 **Cholera Vaccine**

Introduction

Dr. Pablo Sanchez (ACIP, WG Chair)

Introduction to cholera and cholera vaccines

Dr. Jennifer Collins (CDC/NCEZID)

Vaxchora safety and immunogenicity data

Dr. James McCarty (Emergent BioSolutions)

Work group plans

Dr. Jennifer Collins (CDC/NCEZID)

3:25 **Orthopoxviruses Vaccines**

Introduction

Dr. Beth Bell (ACIP, WG Chair)

Workgroup considerations

Dr. Brett Petersen (CDC/NCEZID)

Updated policy questions and progress on systematic review

Dr. Agam Rao (CDC/NCEZID)

Summary and next steps

Dr. Brett Petersen (CDC/NCEZID)

5:35 **Adjourn**

**Acronyms**

CDC Centers for Disease Control and Prevention

CMS Centers for Medicare and Medicaid Services

COVID-19 Coronavirus disease 2019

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NIAID National Institute of Allergy and Infectious Diseases

OIDP Office of Infectious Disease and HIV/AIDS Policy

PCV15 15-valent pneumococcal conjugate vaccine

PCV20 20-valent pneumococcal conjugate vaccine

PEP Post-exposure prophylaxis

PrEP Pre-exposure prophylaxis

RZV Recombinant zoster vaccine

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization

VE Vaccine Effectiveness